Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 211

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 211
---
6-02.

In June 2016,
the Financial Accounting Standards Board (FASB) issued Accounting Standard Update (ASU) No. 2016-13, Financial Instruments – Credit
Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which replaces the existing incurred loss impairment model
with an expected credit loss model and requires a financial asset measured at amortized cost to be presented at the net amount expected
to be collected. The guidance was effective for the Company beginning January 1, 2023, and interim periods therein. The implementation
of ASU 2016-13 didn’t have material effect on its consolidated financial statements and related disclosures.

In December
2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which simplifies the accounting
for income taxes by removing a variety of exceptions within the framework of ASC 740. These exceptions include the exception to the incremental
approach for intraperiod tax allocation in the event of a loss from continuing operations and income or a gain from other items (such
as other comprehensive income), and the exception to using general methodology for the interim period tax accounting for year-to-date
losses that exceed anticipated losses.

<div align='center'>F-20</div>

REVIUM RX.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands

NOTE 3 – ACQUISITION

The Company accounted for the following
transaction as a business combination and allocated the purchase consideration to assets acquired and liabilities assumed based on their
estimated fair values.

On November 14, 2023, the Company entered
into the Stock Exchange Agreement (the “Share Exchange Agreement”) with Predecessor.(formerly known as LipoVac Ltd), an Israeli
company (“LipoVation”) and the shareholders of Predecessor pursuant to which the former shareholders of LipoVation have agreed
to contribute all of their shareholdings in Predecessor in exchange for the right to receive shares of the Company’s common stock.
On July 23, 2024, the transactions contemplated under the Stock Exchange Agreement were closed and as a result Predecessor became a wholly
owned subsidiary of the Company.

In consideration for the contribution
of all of their shareholdings in Predecessor to the Company, the Company issued to the former Predecessor shareholders an aggregate of
23,171